WVE

WVE

USD

Wave Life Sciences Ltd. Ordinary Shares

$8.010+0.000 (0.000%)

Цена в режиме реального времени

Healthcare
Биотехнология
Сингапур

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$8.010

Максимум

$8.270

Минимум

$7.950

Объем

1.95M

Фундаментальные показатели компании

Рыночная капитализация

1.3B

Отрасль

Биотехнология

Страна

Singapore

Статистические данные торговли

Средний объем

2.52M

Биржа

NGM

Валюта

USD

52-недельный диапазон

Минимум $5.28Текущая $8.010Максимум $16.74

Связанные новости

GlobeNewswire

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or

Просмотреть больше
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
GlobeNewswire

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will

Просмотреть больше
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
GlobeNewswire

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under "WVE-007 (GalNAc-siRNA)" – "Next steps."

Просмотреть больше
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
GlobeNewswire

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well

Просмотреть больше
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Analyst Upgrades

Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences with a Buy rating and announces Price Target of $22.

Просмотреть больше
Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.